Symbolbild · KI-generiert
Lobe Sciences Ltd.
Stock factsheet
Company data from public sources (TMX Money, Canadian Securities Exchange, Nasdaq screener, Wikidata); every ISIN is verified against its check digit. Where „—“ appears, no verified value exists — we do not publish unverified identifiers. Market capitalisation is an order of magnitude as of the date shown, not a real-time figure. The size class follows the thresholds in common use (micro < $300m, small < $2bn, mid < $10bn) and is meant as an indication, not a definition.
Company profile
Lobe Sciences is a biopharmaceutical company focused on developing medicines to treat diseases with unmet medical needs. The Company, through collaboration with industry-leading partners, is engaged in novel research and development focused on treating chronic cluster headache (an orphan disease), refractive anxiety, and sickle cell disease. The Company is engaged in Phase 1 and Phase 2 activities in its drug portfolio, and intends to initiate the launch of Altemia®, a medical food designed to meet the needs of sickle cell patients globally.
Company description as published by the issuer via Canadian Securities Exchange.
Comparable companies
Companies in the Biotech & Pharma sector of a similar size.
| Company | Ticker | Exchange | Market cap |
|---|---|---|---|
| Lobe Sciences Ltd. | LOBE | CSE | 15 Mio. USD |
| VentriPoint Diagnostics Ltd. | VPT | TSXV | 15 Mio. USD |
| Conavi Medical Corp. | CNVI | TSXV | 15 Mio. USD |
| MustGrow Biologics Corp. | MGRO | TSXV | 16 Mio. USD |
| Defence Therapeutics Inc | DTC | CSE | 16 Mio. USD |
| Alzai Health Corp. | ALZI | TSXV | 17 Mio. USD |
| Principal Technologies Inc. | PTEC | TSXV | 13 Mio. USD |
Investor Relations
We link only to primary sources from the company itself and from the regulators. Fields we have not recorded stay empty until a reliable source is available.
Information and education only — not investment advice, not a recommendation and not a financial analysis within the meaning of §85 WpHG or Art. 20 MAR. Investments in small and micro caps are highly speculative; total loss is possible. All information without warranty.